Global preimplantation genetic diagnosisis market expected to reach USD 96.8 million by 2024, according to a new report by Grand View Research, Inc. This expected growth in demand can be ascribed to the growing incidence of inherited single gene associated and late onset genetic disorders.
Ongoing introduction of advancements in in-vitro fertilization (IVF) methods are key factors that have a positive impact on the growth of this market. Incorporation of novel algorithms pertaining to genetic diagnosis using NGS technology are expected to fuel demand in the coming years.
Demand for successful embryo implantation in couples who are detected with certain chromosomal aberrations or fertility problems are also factors anticipated to boost growth in demand over the forecast period.
View
summary of this report @ http://www.grandviewresearch.com/industry-analysis/preimplantation-genetic-diagnosis-market
Further key findings from the study suggest:
·
Chromosomal abnormalities accounted for over 36%
of the revenue generated in 2015. This large share can be attributed to growing
usage of PGD techniques for detection of aneuploidies that are observed in
higher aged maternal patients. Furthermore, presence of large product portfolio
of different market players operating in chromosomal abnormality detection is
responsible for large market share of this technique.
·
Embryo HLA typing for stem cell therapy
accounted for over 32% of the revenue generated in the market for 2015. High
incidence rate of single gene disorders and late onset hereditary oncology
diseases that need to be treated in order to curb the mortality rate are major
driver for growth of this segment.
·
Embryo implantation for treatment of the first
child that is inherited with the chromosomal abnormality by the virtue of
‘savior sibling’ is attributive towards market growth. With expected
development of this segment, the market will witness lucrative opportunities of
growth over the forecast period.
·
North America dominated the market in 2015, with
revenue estimated at over USD 35 million in 2015. Presence of sophisticated
healthcare infrastructure, rising aneuploidy, and infertility rates, favorable
government initiatives with respect to genetic diagnosis and its application in
IVF are major factors driving growth of this region.
·
Asia Pacific is expected to witness lucrative
growth from 2016 to 2024 due to the availability of cost-effective PGD
procedures coupled with rapidly rising healthcare R&D investment, and
growing medical expenditures in emerging economies of India and China.
·
Key participants of the preimplantation genetic
diagnosis market include Genesis Genetics, LabCorp, Natera, Quest Diagnostics,
Genea, Genzyme Corporation, Reproductive Genetics Institute, and F. Hoffman La
Roche Ltd.
·
These participants are involved in R&D for
development of tests that can detect several chromosomal abnormalities using
single cell analysis and prevent inheritance of genetic imbalances.
Browse
more reports of this category by Grand View Research: http://www.grandviewresearch.com/industry/biotechnology
Grand View Research has segmented preimplantation genetic diagnosis market on the basis of product, application, and region:
Global Preimplantation Genetic Diagnosis Outlook, by Type (Market Revenue in USD Million, 2013 - 2024)
·
Chromosomal Abnormalities
·
HLA Typing
·
X-linked Diseases
·
Gender Selection
·
Other Genetic Disorders
Global Preimplantation Genetic Diagnosis Application Outlook (Market
Revenue in USD Million, 2013 - 2024)
·
Embryo HLA Typing for Stem Cell Therapy
·
IVF Prognosis
·
Late Onset Genetic Disorders
·
Inherited Genetic Diseases
·
Others
Preimplantation Genetic Diagnosis Regional Outlook (Market Revenue
in USD Million, 2013 - 2024)
·
North America
o
U.S.
o
Canada
·
Europe
o
Germany
o
UK
·
Asia Pacific
o
Japan
o
China
·
Latin America
o
Brazil
o
Mexico
·
Middle East and Africa
o
South Africa
For press release of this report - http://www.grandviewresearch.com/press-release/global-preimplantation-genetic-diagnosis-pgd-market
About Grand View
Research
Grand
View Research, Inc. is a U.S. based market research and consulting company,
registered in the State of California and headquartered in San Francisco. The
company provides syndicated research reports, customized research reports, and
consulting services. To help clients make informed business decisions, the
company offers market intelligence studies ensuring relevant and fact-based
research across a range of industries including technology, chemicals,
materials, healthcare and energy.
Contact:
Sherry
James
Corporate
Sales Specialist, U.S.A.
Grand
View Research, Inc.
United
States
Phone: 1-415-349-0058
Toll
Free: 1-888-202-9519
Email: sales@grandviewresearch.com
No comments:
Post a Comment